Isthmin-1 as a Biomarker of Disease Activity in Rheumatoid Arthritis: Correlation With Musculoskeletal Ultrasound Findings

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorAmera Imam Abdel - Ghany Ahmed

About this trial

The goal of this case control study is to detect serum isthmin-1 level in RA patient compered to healthy control . The main questions it aims to answer are:

what is the serum isthmin-1 level in RA patient? what is the correlation between serum isthmin-1 and RA disease activity? what is the correlation between serum isthmin-1 level and MSUS finding in RA patients?

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

Patients less than 18 years old.

Patients with other autoimmune diseases.

Participants with active infections, malignancies or diabetes.

Recent hand surgery, trauma, deformity and neurological conditions affecting hand function

Trial population

Adult patients (≥18 years old) clinically diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

66 Participants
are grouped into 2 trial groups
Group A: rheumatoid arthritis patient
Group B: age and sex matched healthy control

Trial outcomes

Primary outcomes

1

Detection of serum isthmin-1 level in RA patients compared to healthy controls.

The quantitative level of Human ISM1 will be measured with a commercial enzyme-linked immunosorbent assay(ELISA) kit.

Time frame
baseline

Secondary outcomes

1

To correlate serum ISM1 levels with disease activity in RA

through clinical and acute phase reactant

Time frame
baseline

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Amera Imam Abdel - Ghany Ahmed

Lead sponsor

Assiut University

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: